Drug intelligence / Profile preview

NRCT-202XR

Development stage: Unknown
Lead developer: Neurocentria
Modality: Small Molecules

Overview

NRCT-202XR is an experimental drug developed by Neurocentria for the treatment of attention-deficit hyperactivity disorder (ADHD). It is classified as a new molecular entity and currently has an undefined mechanism of action. NRCT-202XR is under investigation both as a monotherapy and in combination therapy (with NRCT-101SR) in adolescent patients with ADHD. As of the most recent Phase II clinical trials, more specific pharmacology or route of administration information has not been disclosed[1][3][7][9].

Other names: NRCT-202XRNRCT202XRNRCT 202XRNRCT-202-XRNRCT202-XRNRCT 202-XR

Beyond the preview

Go deeper on NRCT-202XR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NRCT-202XR.

Explore the full profile